Although no formal deal has closed, analysts speculate an acquisition could be imminent, especially in the wake of divestitures from its COVID-era portfolio.[5] , [6] (2024): Novo Nordisks Expansion via Catalent Deal Novo Nordisks US$16.5 billion acquisition of Catalents fill-finish facilities demonstrates another angle of strategic M&A, ensuring capacity for GLP-1 manufacturing and reducing supply chain risks amid skyrocketing demand.[7] Beyond Big Pharma: Biotechs Role as Innovation Engines Small- to mid-cap biotech firms are proving essential in advancing the next frontier of GLP-1 therapies
The Journal of International Medical Research
** ageLOC Me ageLOC Me brought customization to consumers in 2015
Companies have requested and received pediatric exclusivity extensions for cardiac drugs, erectile dysfunction medications, and antihypertensives, categories where pediatric use is minimal
This pricing model means your dose may need to go up, but your price won't, removing cost uncertainty as patients titrate toward their therapeutic range
.jpg)
